Evidence map›Paper›PMID 41274283›Full record

ArticleCell2025

Inhibition of oligomeric BAX by an anti-apoptotic dimer.

Catherine E Newman, Micah A Gygi, Haleh Alimohamadi, Thomas M DeAngelo, Christina M Camara, Julian Mintseris, Ezra Yu, Edward P Harvey, Zachary J Hauseman, Lixin Fan and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Natural Extracts ofAntioxidants (Basel, Switzerland) · 2026
    Article
  2. A unified photosensitizer platform forbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Catherine E NewmanDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Micah A GygiDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Haleh AlimohamadiDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Thomas M DeAngeloDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Christina M CamaraDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Julian MintserisDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Ezra YuDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Edward P HarveyDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Zachary J HausemanDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lixin FanSAXS Facility, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Yun-Xing WangCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Elizabeth W-C LuoDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Marina GodesDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jacob GehtmanDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ann M CathcartDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
John R EngenDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Gregory H BirdDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Gerard C L WongDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Thomas E WalesDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Loren D WalenskyDepartment of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: loren_walensky@dfci.harvard.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Jean Jakoncic · 2019 to 2026
$38.6M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human CancerR35CA197583 · NCI · DANA-FARBER CANCER INST · PI Loren David Walensky · 2015 to 2026
$12.5M
New Sample Multiplexing Technologies to Identify Chemical Probes and Illuminate Ubiquitin BiologyR01GM067945 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GYGI, STEVEN P · 2003 to 2024
$10.5M
Vascular Biology Training GrantT32HL069766 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2002 to 2022
$7.4M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human CancerR50CA211399 · NCI · DANA-FARBER CANCER INST · PI Gregory Howard Bird · 2016 to 2026
$3.2M
A Simultaneous SAXS/WAXS Detector System for Solving Biological StructuresS10OD012331 · OD · STATE UNIVERSITY NEW YORK STONY BROOK · PI ALLAIRE, MARC · 2012 to 2012
$1.1M
Nanobodies for Dissecting the Structure and Function of Oligomeric BAXF30CA275293 · NCI · HARVARD MEDICAL SCHOOL · PI Ellen Yu · 2023 to 2026
$185k
Structure-Function Analysis of a Novel Inhibitory Mechanism for Pro-Apoptotic BAKF31CA210590 · NCI · DANA-FARBER CANCER INST · PI HAUSEMAN, ZACHARY JOEL · 2016 to 2019
$173k
Dissecting the Mitochondrial Translocation Mechanism of Anti-Apoptotic BCL-wF31CA210592 · NCI · DANA-FARBER CANCER INST · PI HARVEY, EDWARD PAUL · 2016 to 2019
$154k
NCI NIH HHS F30 CA264846NCI NIH HHS F30 CA275293NCI NIH HHS F31 CA210590NCI NIH HHS F31 CA210592NCI NIH HHS R35 CA197583NCI NIH HHS R50 CA211399NHLBI NIH HHS T32 HL069766NIDDK NIH HHS R01 DK117850NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM067945NIGMS NIH HHS T32 GM144273NIH HHS 75N91019D00024NIH HHS S10 OD012331
6 · The paper itself

Abstract

BAX is a pro-apoptotic BCL-2 protein that resides in the cytosol as a monomer until triggered by cellular stress to form an oligomer that permeabilizes mitochondria and induces apoptosis. The paradigm for apoptotic blockade involves heterodimeric interactions between pro- and anti-apoptotic monomers. Here, we find that full-length BCL-w forms a distinctive, symmetric dimer (BCL-w

Indexed as

Apoptosisbcl-2-Associated X ProteinAnimalsHumansMitochondriaProtein MultimerizationProto-Oncogene Proteins c-bcl-2Scattering, Small Anglebcl-2-Associated X ProteinProto-Oncogene Proteins c-bcl-2anti-apoptoticapoptosisBAXBCL-2 family proteinsBCL-wcell deathchemical crosslinking mass spectrometrydimerhydrogen deuterium exchange mass spectrometrymembrane curvaturemitochondriamitochondrial retrotranslocationmitochondrial translocationoligomerpro-apoptoticsmall-angle X-ray scattering

Identifiers

PMID41274283
PMCPMC13200811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.